Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 208,892	$ 304,962
Short-term investments	50,441	0
Accounts receivable	22,934	12,388
Inventories, net	34,394	16,136
Prepaid clinical development costs	1,138	844
Other prepaid and current assets	11,173	11,566
Total current assets	328,972	345,896
Restricted cash	50,000	0
Property and equipment, net	664	1,276
Right of use operating lease assets	1,898	6,030
Intangible assets	56	56
Total assets	381,590	353,258
Current liabilities:
Accounts payable	17,559	51,975
Accrued clinical development costs	7,013	7,663
Other accrued liabilities	30,410	24,790
Revenue interest liability	11,295	5,392
Deferred revenue from collaborations	5,683	1,662
Operating lease liabilities	1,392	2,587
Total current liabilities	73,352	94,069
Convertible notes, net of issuance costs	258,280	179,367
Revenue interest liability	245,744	171,212
Operating lease liabilities	524	3,454
Deferred revenue from collaborations	634	0
Other long-term liabilities	0	1,290
Total liabilities	578,534	449,392
Commitments and contingencies (Note 5)
Stockholders’ (deficit) equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of December 31, 2021 and December 31, 2020	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized as of December 31, 2021 and December 31, 2020; 62,873,694 shares issued at December 31, 2021 and 27,910,366 shares issued at December 31, 2020	61	26
Additional paid-in capital	964,401	797,655
Treasury stock, at cost; 1,994,198 shares at December 31, 2021 and December 31, 2020	(54,998)	(54,998)
Accumulated other comprehensive loss	(31)	0
Accumulated deficit	(1,106,377)	(838,817)
Total stockholders' deficit	(196,944)	(96,134)
Total liabilities and stockholders' deficit	$ 381,590	$ 353,258